Diabetes

ACC.24 – In patients with diabetic cardiomyopathy and reduced exercise tolerance, the aldose reductase inhibitor AT-001 did not improve exercise tolerance as measured by change in peak VO₂ compared with placebo

p>This summary is based on the presentation of James Januzzi Jr., MD (Boston, MA, US) at the ACC.24 Scientific Session – A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyop...

ACC.24 - A remote program comprising simultaneous patient education and medication management increased SGLT2i and GLP-1RA prescriptions at 6 months in T2D patients at elevated CV and/or renal risk compared with an approach providing education first followed by medication management.

This summary is based on the presentation of Alexander Blood, MD (Boston, MA, USA) at the ACC.24 Scientific Session - The Diabetes Remote Intervention To Improve Use Of Evidence-based Medications (dri...

ACC.24 – In patients with obesity-related HFpEF and T2D, semaglutide resulted in larger reductions in HF-related symptoms and physical limitations, greater weight loss, and greater improvement in exercise function at 52 weeks compared with placebo.

This summary is based on the presentation of Mikhail Kosiborod, MD (Kansas City, MO, USA) at the ACC.24 Scientific Session - Once-weekly Semaglutide In Patients With Heart Failure With Preserved Eject...

A meta-analysis of very large cohorts showed that foods with a high glycemic index were associated with T2D, CVD, diabetes-related cancer, and all-cause mortality. Diets high in fiber or whole grains showed reductions similar to those seen for low-GI foods.

This summary is based on the publication of Jenkins DJA, Willett WC, Yusuf S, et al. - Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-c...

In the FLOW trial, treatment with semaglutide reduced the risk of the primary composite endpoint of kidney disease progression, or death from kidney disease or CVD by 24% in people with T2D and CKD.

The headline results from the FLOW trial have been announced. Treatment with semaglutide 1.0 mg reduced the primary composite endpoint of kidney disease progression, or death from kidney disease or CV...

In a prespecified secondary analysis of EMPA-KIDNEY, empagliflozin reduced progression of CKD in different subgroups of patients with CKD, including in patients with little albuminuria.

This summary is based on the publication of EMPA-KIDNEY Collaborative Group - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY ...

AHA 2023 The AHA has developed new equations for CVD risk assessment with optional equations that include cardiovascular-kidney-metabolic (CKM) health and the endorsement of the life course perspective on prediction and prevention of CVD.

Presented at the AHA Scientific Sessions 2023 by: Sadiya Khan, MD - Chicago, IL, US

Intr...

AHA 2023 In the registry-based randomized clinical trial DAPI-MI, dapagliflozin improved cardiometabolic outcomes in patients with acute MI and impaired LV systolic function without diabetes or chronic HF compared with placebo.

Presented at the AHA Scientific Sessions 2023 by: Stefan James, MD, PhD - Uppsala, Sweden

Introduction and me...

A study estimated the lifetime benefit of SGLT2 inhibitor and nonsteroidal MRA combination treatment versus conventional therapy. Treatment with canagliflozin plus finerenone reduced the risk of adverse renal outcomes by 50% in patients with T2D and CKD compared with conventional therapy only.

The American Heart Association has published a scientific statement on the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome.

The American Heart Association (AHA) published a summary on the evidence and fundamental gaps related to the science, screening, prevention, and management on cardiovascular-kidney...

A population-based cohort study showed that cardio-renal-metabolic conditions (CVD, CKD, and T2D) and their overlap were increasingly common among US adults over the last 2 decades.

The FLOW trial, a dedicated kidney outcomes trial with semaglutide in patients with T2D and CKD, will be stopped early due to meeting pre-specified efficacy criteria in the interim analysis.

The FLOW trial, a dedicated kidney outcomes trial with semaglutide in patients with T2D and CKD, will be stopped early due to meeting pre-specified efficacy criteria in the interim...

EASD 2023 A real-life study investigated the prescription on glucose lowering agents in Swedish patients with T2D and CAD from 2010 to 2021.

Presented at the EASD 2023 by: Pia Lundman, MD, PhD - Stockholm, Sweden

Introduction and methods

Several RCTs ...

EASD 2023 A small randomized study showed that treatment with GLP-1RA semaglutide on top of empagliflozin did not have an additional beneficial effect on albuminuria in patients with T2D and albuminuria compared with placebo.

Presented at the EASD annual meeting 20...

EASD 2023 In patients with T2D and HFmrEF/HFpEF, the treatment effect of dapagliflozin on the primary outcome was consistent across the number and most types of baseline glucose-lowering therapies.

Pre...

Empagliflozin has been approved by the FDA for the treatment of adults with CKD.

The FDA approved the SGLT2 inhibitor empagliflozin for the treatment of adults with CKD to reduce the risk of sustained decline in eGFR, end-stage kidney disease, CV death and...